Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, BIOCRYST PHARMACEUTICALS, INC. reported revenue of $875M, up 94.1% year over year. Operating margin was 39.0% and net margin 30.2%, on a free-cash-flow margin of 39.4% with capital expenditure at 0.3% of revenue. Every figure is computed directly from BCRX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $875M | 39.0% | 30.2% |
| FY2024 | $451M | -0.6% | -19.7% |
| FY2023 | $331M | -31.3% | -68.4% |
| FY2022 | $271M | -54.8% | -91.2% |
| FY2021 | $157M | -113.1% | -117.1% |
How does BCRX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.